Available Technology

Lenalidomide Analogs for the Treatment of Neurodegenerative Disorders and Cancer

Inflammatory processes associated with the over-production of tumor necrosis-alpha (TNF-alpha), a potent activator of the immune system accompany numerous neurodegenerative diseases. TNF-alpha has been validated as a drug target with the development of the inhibitors Enbrel and Remicade (fusion antibodies) as prescription medications. Both, however, are large macromolecules that require direct injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of immunologically-mediated and infectious diseases, and cancers. The NIA inventors developed and assessed novel thio analogs of lenalidomide (Celegene's Revlimid and an analog of thalidomide) as immunomodulatory agents, with the potential to reduce chronic systemic and central nervous system inflammation. These compounds were synthesized and evaluated for their TNF-alpha inhibitory activity. This invention was extended from the inventors' prior work to develop potent compounds to reduce neuroinflammation as a treatment strategy for neurodegenerative disorders. The current studies focus the compounds activity in classical models of neurodegeneration as well as cancer.
Abstract: 
Inflammatory processes associated with the over-production of tumor necrosis-alpha (TNF-alpha), a potent activator of the immune system accompany numerous neurodegenerative diseases. TNF-alpha has been validated as a drug target with the development of the inhibitors Enbrel and Remicade (fusion antibodies) as prescription medications. Both, however, are large macromolecules that require direct injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of immunologically-mediated and infectious diseases, and cancers. The NIA inventors developed and assessed novel thio analogs of lenalidomide (Celegene's Revlimid and an analog of thalidomide) as immunomodulatory agents, with the potential to reduce chronic systemic and central nervous system inflammation. These compounds were synthesized and evaluated for their TNF-alpha inhibitory activity. This invention was extended from the inventors' prior work to develop potent compounds to reduce neuroinflammation as a treatment strategy for neurodegenerative disorders. The current studies focus the compounds activity in classical models of neurodegeneration as well as cancer.
Benefits: 
Effective smaller molecular weight compound that can enter brain among current agents -Experimental therapeutic to reduce inflammation systematically and within the brain -More effective in reducing proinflammatory cytokines than existing agents
applications: 
Inventors: 

David Tweedie (NIA)

Weiming Luo (NIA)

Nigel Greig (NIA)

Qian-sheng Yu (NIA)

Harold Holloway (NIA)

Harold Holloway(NIA)
-Qian-sheng Yu (NIA)
-Nigel Greig (NIA)
-Weiming Luo (NIA)
-David Tweedie (NIA)

Patent Number: 
14/571,138
Internal Laboratory Ref #: 
E-045-2012/0
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin